You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 294 No. 16, October 26, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (24)
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Similar articles in JAMA
 Topic Collections
 •Men's Health, Other
 •Urinary Tract Disorders
 •Diagnosis
 •Alert me on articles by topic

Relevance of Urine Telomerase in the Diagnosis of Bladder Cancer

Maria Aurora Sanchini, MSc; Roberta Gunelli, MD; Oriana Nanni, MSc; Sara Bravaccini, BSc; Carla Fabbri, MSc; Alice Sermasi, BSc; Eduard Bercovich, MD; Alberto Ravaioli, MD; Dino Amadori, MD; Daniele Calistri, PhD

JAMA. 2005;294:2052-2056.

Context  The identification of new molecular markers is one of the most challenging goals for the early detection of bladder cancer because available noninvasive methods have neither sufficient sensitivity nor specificity to be acceptable for routine use.

Objective  To develop a relatively simple, inexpensive, and accurate test that measures telomerase activity in voided urine to apply to large-scale screening programs for bladder cancer detection.

Design, Setting, and Participants  Case-control study conducted in 218 men (84 healthy individuals and 134 patients at first diagnosis of histologically confirmed bladder cancer), frequency matched by age and recruited between March 2003 and November 2004 in Italy. Urine telomerase activity was determined using a highly sensitive telomeric repeat amplification protocol (TRAP) assay. Urine samples were processed for cytological diagnosis and TRAP assay. The diagnosis of bladder cancer was based on bioptic and cystoscopic examinations. The performance of the TRAP assay to detect urine telomerase activity was compared with urine cytology as an aid to early cancer detection. Quantification of urine telomerase activity was conducted in a blinded manner.

Main Outcome Measure  Sensitivity and specificity of TRAP to detect bladder cancer.

Results  Using a 50 arbitrary enzymatic unit cutoff value, we validated the results obtained in the pilot study. In the overall series, sensitivity was 90% (95% confidence interval [CI], 83%-94%) and specificity was 88% (95% CI, 79%-93%). Specificity increased to 94% (95% CI, 85%-98%) for individuals aged 75 years or younger. The same predictive capacity of telomerase activity levels was observed for patients with low-grade tumors or with negative cytology results.

Conclusions  The present validation study demonstrated the ability of urine telomerase activity levels to accurately detect the presence of bladder tumors in men. This test represents a potentially useful noninvasive diagnostic innovation for bladder cancer detection in high-risk groups such as habitual smokers or in symptomatic patients.


Author Affiliations: Division of Oncology and Diagnostics (Mss Sanchini and Bravaccini and Dr Calistri) and Department of Urology (Drs Gunelli and Bercovich), Morgagni-Pierantoni Hospital, Forlì, Italy; Istituto Oncologico Romagnolo, Forlì, Italy (Ms Nanni); Department of Oncology, Infermi Hospital, Rimini, Italy (Mss Fabbri and Sermasi and Dr Ravaioli); and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Forlì-Meldola, Italy (Dr Amadori).


RELATED LETTERS

Urine Telomerase and Bladder Cancer Detection
Brian C.-S. Liu
JAMA. 2006;295(9):998.
EXTRACT | FULL TEXT  

Urine Telomerase and Bladder Cancer Detection
Steffen Weikert, Frank Christoph, and Kurt Miller
JAMA. 2006;295(9):998-999.
EXTRACT | FULL TEXT  

Urine Telomerase and Bladder Cancer Detection—Reply
Maria Aurora Sanchini, Oriana Nanni, and Daniele Calistri
JAMA. 2006;295(9):999.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Molecular Markers of Urothelial Cancer and Their Use in the Monitoring of Superficial Urothelial Cancer
Black et al.
JCO 2006;24:5528-5535.
ABSTRACT | FULL TEXT  

Urine Telomerase and Bladder Cancer Detection
Liu
JAMA 2006;295:998-998.
FULL TEXT  

Urine Telomerase and Bladder Cancer Detection
Weikert et al.
JAMA 2006;295:998-999.
FULL TEXT  

Surveillance for Recurrent Bladder Cancer Using a Point-of-Care Proteomic Assay
Grossman et al.
JAMA 2006;295:299-305.
ABSTRACT | FULL TEXT  

New Approach to Screening for Bladder Cancer?
JWatch General 2005;2005:1-1.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.